Business Wire

Study Shows HK L-137 Reduces Inflammation in Healthy Overweight Individuals — Takes Front Line Against Metabolic Syndrome

Share

There’s a reason why the health-conscious focus has turned toward foods, supplements and behaviors to reduce inflammation. It’s why House Wellness Foods has put decades of meticulous research into the anti-inflammatory benefits of its unique immunobiotic Lactobacillus plantarum HK L-137, the primary ingredient of its Immuno-LP20®. A just-published study illuminates how this bacillus, in its nonviable form, can be especially important, even lifesaving, to those contending with obesity.

Inflammation is a bodily response we rely on to counter stress, infection and external toxins. But we know that it is also one of the keystones of metabolic dysfunction. Many have gone as far as to suggest that inflammation is the defining characteristic of all infirmity, including the depredating aspects of the aging process itself, leading to eventual organ failure. Unchecked, it can cause the decline of overall health, is linked to a string of metabolic complications, and implicated in dozens of autoimmune diseases from lupus to MS.

Notably, even otherwise healthy individuals under the stress associated with high body mass can suffer a rapidly deteriorating downward spiral; and as we know, obesity is among the most prevalent disease factors in post-industrial society worldwide, (affecting about 40 percent of the U.S. population alone). Simply put, production of inflammatory cytokines increases in individuals carrying more body fat. Though the popular literature avoids the harsh details, the manifestation of this destructive cycle includes insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, hypertension, and dyslipidemia.

The new study from House Wellness Foods laboratories, in cooperation with the Medical Institute of Bioregulation, Kyushu University, describes in detail the process by which inflammation sets its destructive effects in motion. Adipose tissue produces an abundance of inflammatory cytokines, resulting in elevated serum levels of inflammatory mediators (C-reactive protein and leukocyte concentration among them). Tumor necrosis factor and interleukin induce systemic insulin resistance and affect lipid metabolism. There is a concomitant elevation of the serum levels of triglycerides and very-low-density lipoprotein (VLDL).

In the inflammation response, cells communicate via extraordinarily complex means to protect muscles and organs in bodies subjected to ordinary stress or injury. The research paper defines the consequences of lingering inflammation, such as that associated with overweight, and how the inflammatory mediators present in obese or overweight persons need to be suppressed to thwart associated metabolic disorders such as insulin resistance and hyperlipidemia.

Lactic acid-based bacterial probiotics have long shown effectiveness in immune modulation and lipid metabolism. Viable lactobacilli in foods like kefir and other probiotic boosters have proved valuable in lowering total cholesterol levels, but their effect is limited both by their chemistry and the mechanisms by which they act on the body. Multiple peer-reviewed studies have shown that nonviable bacilli, like (heat-killed) HK L-137, are equally, and in many instances more effective in improving obesity-induced inflammation and abnormalities of lipid metabolism, with a more profound impact on immune response as gauged by multiple measurements including enhanced Th1-related immune functions, such as concanavalin A (Con A)-induced proliferation in T cell production.

Heat-killing’s advantage is that it strengthens the bacterial organism’s cellular barriers and fixes its biogenetic material. It stands up to gastric fluids and remains intact through to the ileum of the small intestine, to go on to spur immune response in the mucosa. Heat-killing is what gives HK L-137, the prime constituent of House’s Immuno-LP20, its character as an immunobiotic, and as multiple peer-reviewed studies show, its cell protective and regenerative function supports quality of life improvements that include dramatic reduction of upper respiratory infection and periodontal disease. It also makes HK L-137 available for the widest range of applications due to its ability to withstand processing. Nonviability gives it an unparalleled shelf life without diminishing its effectiveness.

House Wellness Foods has devoted nearly 30 years to both the clinical study of the immunological and protective properties of HK L-137, and the refinement of its natural, food product-based production. The apex of its efforts is Immuno-LP20®, its functional immunobiotic based on HK L-137.

Metabolic syndrome is a crisis of global proportion. Countering it, House Wellness Foods, in its supplements and functional food products, has concentrated its focus on supporting the body’s innate ability to bolster immunity and restore vitality at the cellular level. It is a quest for nothing less than the sustenance of superior health and vigor, and the extension of all life on the planet.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kotaro Soga
House Wellness Foods Corp.
s-hirayama@housefoods.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer21.10.2025 08:17:00 EEST | Press release

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, presented results from the Phase 1b dose escalation of the TheraPb Phase 1/2 clinical trial (NCT05720130) at the European Society for Medical Oncology (ESMO) 2025 congress. The presentation featured the first clinical results of 212Pb-ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy in mCRPC. “We are very encouraged by the completion of the treatment period of our Phase 1 trial, which has demonstrated a favorable safety profile and compelling anti-tumor activity for 212Pb-ADVC001," said Anna Karmann, MD PhD, Chief Medical Officer of AdvanCell. “These results underscore the potential of our therapy to meaningfully impact patients’ lives and advance treatment options in metastatic prostate cancer. I want to sincerely thank the investigators, clinical teams, and most importantly the patients and their families, whose commitment has made this important milestone pos

GigaDevice Deepens Commitment to Japan, Advancing Local Services and Global Collaboration21.10.2025 06:57:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially opened its new office in Minato City, Tokyo. This milestone reflects the company’s deepening commitment to the Japanese market and marks a significant step in enhancing local customer support, strengthening regional collaboration, and advancing its global development efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020247226/en/ GigaDevice executives and employees celebrate the opening of the new Japan office in Minato City, Tokyo. Japan has long served as a vital pillar of GigaDevice’s global strategy. Over the years, the company has expanded its local team, refined operation to meet evolving customer needs, and established a responsive professional service system. This new office will further enhance GigaDevice’s technical responsiveness and agility, foster closer

Streamlining Project Efficiency with Murata’s Pre-Installed Electrical Models in the Latest Versions of Cadence OrCAD X Capture™, Allegro X System Capture™ and AWR Design Environment™ (Microwave Office)21.10.2025 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a significant collaboration with Cadence Design Systems, Inc., making product libraries directly accessible within Cadence’s leading Electronic Design Automation (EDA) tools. Murata’s selected inductor and capacitor products are now pre-installed in the latest versions of Cadence OrCAD X Capture™, Allegro X System Capture™ and AWR Design Environment™ (Microwave Office). By enabling engineers to select Murata components directly within these tools and run simulations, this initiative is set to refine circuit design and streamline the design process for power supply, high-frequency, and noise suppression circuits. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020071479/en/ [Murata Manufacturing Co., Ltd.] Collaboration with Cadence Design Systems, Inc. Advancements in IC performance and increased circuit complexity on PCBs are driving the industry

Rigaku opens Rigaku Technology Center Taiwan20.10.2025 18:00:00 EEST | Press release

Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a new group company in Taiwan, in 2025. A facility within RTTW, Rigaku Technology Center Taiwan (hereinafter RTC-TW), began full-scale operation in October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020130286/en/ Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park RTTW will assume duties formerly managed by Rigaku Taiwan Branch (RCTW), established in 2024. As Rigaku’s base of operations in Chinese-speaking East Asia, RTTW aims to strengthen customer support and advance sustainable growth in the region. RTC-TW will serve as an engineering base for advancing R&D, customer support, and joint development. The facility will include a clean room that replicates actual production environments, along w

InterSystems and Google Cloud Integrate InterSystems HealthShare with Google Cloud’s Healthcare API20.10.2025 17:00:00 EEST | Press release

InterSystems, a creative data technology provider managing over one billion health records worldwide, today announced a new partnership that integrates InterSystems HealthShare with Google Cloud. Announced at HLTH, this collaboration aims to deliver a scalable, real-time, harmonized data foundation for generative and agentic AI applications. The partnership addresses one of the most pressing challenges in healthcare IT: fragmented and inconsistent data. By combining InterSystems expertise in data harmonization, identity resolution, and interoperability with Google Cloud’s broad suite of AI-enabled analytics and search capabilities and secure infrastructure, healthcare organizations can now unlock the full potential of AI with clean, unified, and actionable data on a proven, enterprise-grade cloud platform. “AI is transforming healthcare, but it can only succeed when it’s grounded in reliable, actionable data,” said Don Woodlock, head of Global Healthcare Solutions at InterSystems. “By

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye